Mesoblast MESO 深 沪
等待开盘 08-20 09:30:00 美东时间
17.13
+0.460
+2.76%
华盛通- 最 高17.14
- 今 开16.85
- 成交量 13.25万股
- 最 低 16.78
- 昨 收 16.67
- 总市值 22.22亿
- 52周最高 21.50
- 市盈率 静 --
- 换手率 0.10%
- 52周最低 12.66
- 委 比 -86.84%
- 总股本 1.30亿
- 历史最高 58.4372
- 量 比 0.57
- 振 幅 2.16%
- 历史最低 1.9406
- 每 手 1
- 风险率 1.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial
Mesoblast Limited ( ($AU:MSB) ) has issued an announcement. Mesoblast has compl...
08-17 08:24
Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Friday. Shares of Swarmer Inc (NASDAQ:SWMR) fell sharply in pre-market trading after the company reported worse-than-expected quarterly financial results. Swarmer reported quarterly losses of 45 cents per share w...
08-14 20:06
Analysts Are Bullish on These Healthcare Stocks: Mesoblast Limited (MEOBF), Cullinan Management (CGEM)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-07 07:40
State Street Group Cuts Mesoblast Stake Below Substantial Holder Threshold
An update from Mesoblast Limited ( ($AU:MSB) ) is now available. State Street C...
08-03 15:44
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
Mesoblast Limited reported strong performance in Q4 FY2026, with Ryoncil® generating $36 million in net revenue and $115 million for the full year post-FDA approval. The company is expanding Ryoncil's indications to adults with steroid-refractory acute GvHD and other severe inflammatory diseases. Rexlemestrocel-L met its target of 300 patients in a pivotal Phase 3 trial for chronic low back pain. Mesoblast also unveiled next-generation MSC strate...
07-30 00:57
State Street Exits Substantial Holding in Mesoblast
An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblas...
07-24 15:17
Mesoblast Cancels Over 1.2 Million Lapsed Options
Mesoblast Limited ( ($AU:MSB) ) has issued an announcement. Mesoblast Limited h...
07-14 15:47
Mesoblast Issues 8.2 Million Unquoted Employee Options
An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblas...
07-14 15:31
Mesoblast posts US$115m first-year Ryoncil revenue and strengthens capital position
Mesoblast Limited ( ($AU:MSB) ) has shared an announcement. Mesoblast reported ...
07-10 08:07
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
Mesoblast Limited reported net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026, driven by strong uptake of Ryoncil®. CEO Dr. Silviu Itescu expressed satisfaction with revenue exceeding initial projections and anticipates continued growth in the next fiscal year. Ryoncil®, the first FDA-approved mesenchymal stromal cell (MSC) product, is the only treatment for steroid-refractory acute graft-versus-...
07-10 00:30
